

FORMALITIES LETTER



OC000000005125932

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark OfficeAddress COMMISSIONER OF PATENT AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/522,342	03/09/2000	Timothy A. Stewart	A-68670/RMS/DAV

Flehr Hohbach Test
Albritton & Herbert LLP
Suite 3400
Four Embarcadero Center
San Francisco, CA 94111-4187

Date Mailed: 05/18/2000

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.
Applicant must submit \$ 690 to complete the basic filing fee and/or file a small entity statement claiming such status (37 CFR 1.27).
- Total additional claim fee(s) for this application is \$4796.
 - \$2664 for 148 total claims over 20.
 - \$1872 for 24 independent claims over 3.
 - \$260 for multiple dependent claim surcharge.
- The oath or declaration is missing.
A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):
 - This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c)
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required under 37 CFR 1.821(e).

For questions regarding compliance to these requirements, please contact:


- For Rules Interpretation, call (703) 308-1123
- For CRF Submission Help, call (703) 308-4212
- PatentIn Software Program Support
- For Technical Assistance, call (703) 287-0200
- To Purchase PatentIn Software, call (703) 306-2600

File A-68670 Att DAV
 Due Date 7/18/2000
 Refs 2

July 18, 2000 - Missing Parts
 DUE DATE

- The balance due by applicant is \$ 5616.


A copy of this notice MUST be returned with the reply.




Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Stewart et al. Serial No.: 09/522,342 Filed: March 9, 2000 For: <i>Fibroblast Growth Factor-19 (FGF-19) Nucleic Acids and Polypeptides and Methods of Use for the Treatment of Obesity</i>	Group Art Unit: Unknown Examiner: Unknown <div><p>CERTIFICATE OF MAILING</p><p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p><p>August 18, 2000</p><p> Teri Renshaw</p></div>
---	--

Box: MISSING PARTS
Assistant Commissioner of Patents
Washington, D.C. 20231

This is responsive to the Notice to File Missing Parts dated May 18, 2000. Transmitted herewith are the following documents:

1. Declaration duly executed;
2. Copy of Notice to File Missing Parts of Application (PTO-1533);
3. Notice of Change of Correspondence Address;
4. Preliminary Amendment;
5. Amendment Transmittal;
6. Petition for one Month Extension of Time and requisite fee of \$110;
7. Filing fee and additional claim fees in the amount of \$3760.00, including the surcharge of \$130 for responding to the Notice to File Missing Parts of Application to be charged to Deposit Account No. 07-0630.



Serial No.: 09/522,342
Filed: March 9, 2000

The Commissioner is hereby authorized any fees associated with this communication or credit any overpayment to Deposit Account No. 07-0630. A duplicate of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.


Date: August 18, 2000

By: Mark T. Kresnak

Mark T. Kresnak

Reg. No. 42,767

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-4461
Fax: (650) 952-9881



Patent Docket P1219P1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Application of Timothy A. Stewart et al. Serial No.: 09/522,342 Filed: March 9, 2000 For: <i>Fibroblast Growth Factor-19 (FGF-19) Nucleic Acids and Polypeptides and Methods of use for the Treatment of Obesity</i>	Group Art Unit: Unknown Examiner: Unknown CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on August 18, 2000 Teri Renshaw
---	--

AMENDMENT TRANSMITTAL

BOX: MISSING PARTS
Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated as shown below.

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Additional Fees
Total	75	-	20	55	18	\$990.00
Independent	28	-	3	25	78	\$1,950.00
<u>0</u> Multiple dependent claim(s), if any					260	\$0.00
Total Fee Calculation						\$2,940.00

X

No additional fee is required.

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of **\$3760.00 (which includes the filing fee of \$690.00 as well as the \$130.00 surcharge for responding to the Notice to Filing Missing Parts of Application.)**. **A duplicate copy of this transmittal is enclosed.**

X

Petition for Extension of Time is enclosed.

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

Respectfully submitted,
GENENTECH, INC.

By:

Mark T. Kresnak, Ph.D.
Reg. No. 42,767

Date: August 18, 2000

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-4461
Fax: (650) 952-9881